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Summary. This study was undertaken to deter- 
mine whether hormonal stimulation followed by 
chemotherapy with a cell-cycle specific agent 
would improve the effectiveness of the chemo- 
therapy in a prostatic adenocarcinoma model. 
One hundred Copenhagen rats were randomised 
into 5 equal groups and injected subcutaneously 
with 2 x 107 cells of Dunning G strain prostatic 
adenocarcinoma. The groups were treated in the 
following fashion: i. sham operated controls, 
2. castration, 3. castration and methotrexate, 
4. castration, testosterone and methotrexate 
and 5. castration and testosterone. When the 
turnouts became palpable, all animals received 
the surgery to which they were randornised. Sub- 
sequent hormonal and chemotherapy was started 
1 week thereafter. Therapy was given for 5 con- 
secutive days followed by a 16-day recovery 
period and then continued in a cyclical fashion. 
Serial measurements of animal weights and 
tumour size were obtained. Analysis of turnout 
growth was restricted to the first 29 days of 
therapy because of a rapid decline in animal 
survival beyond that point. 
The group treated with castration, testos- 
terone, and methotrexate inhibited tumour growth 
more than any other group and was the only group 
that was significantly different from control 
(P < O. 05). 
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INTRODUCTION 
The Dunning R-3327 prostatic carcinoma origi- 
nated from a spontaneous neoplasm in an aged 
Copenhagen rat (3). The G sub-line has been 
characterised as a rapidly-growing transplantable 
turnout that is hormonally responsive (I). This 
study was undertaken to evaluate the effects of 
androgen on the response of the turnout to chemo- 
therapy with a cell cycle-specific agent in the 
previously castrated animal. The rate of DNA 
synthesis in prostatic tissue of castrated rats 
increases 24 h following daily parenteral exoge- 
nous testosterone administration and peaks at 
72 h (2). To assess the effect of androgen on the 
response of the hormonally responsive prostatic 
neoplasm to chemotherapy, castrated Copenhagen 
rats bearing transplanted G strain tumours were 
treated with testosterone and/or methotrexate 
with appropriate controls. 
MATERIAL AND METHODS 
One hundred Copenhagen rats I, age 14 weeks, 
were randomly assigned to 5 groups of 20 each 
and injected subcutaneously in the left flank with 
2 x 107 cells of R-3327-G prostatic adenocar- 
cinoma2. The cell suspension was prepared by 
IThe Copenhagen rats were obtained from the 
National Cancer Institute, Bethesda, Maryland 
2The R-3327-G cell line was obtained from Dr. 
Norman Block, Jackson Memorial Hospital, 
Miami, Florida and has been maintained in our 
laboratory by serial transplantation in Copen- 
hagen rats since 1977 
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mincing freshly excised tumour from a stock 
animal in RPMI 1640. The minced tumour was 
dispersed by stirring in 0.5% trypsin with 0.02% 
collagenase at room temperature. The resulting 
mixture was filtered through gauze to eliminate 
large pieces of tumour, washed once in RPMI 
1640, and viable cell counts then determined by 
trypan blue exclusion. The cells were diluted 
with RPMI 1640 to a concentration of 2 x 107 
cells/0.5 ml. All animals had palpable evidence 
of tumours at the injection site 2 weeks there- 
after. 
When the tumours first became palpable (mean 
diam. 0. 74 cm) all animals either underwent a 
sham operation (Group i) or were castrated. 
Groups 1 (sham operated) and 2 (castrated) 
received no additional therapy. The remainder 
of the castrated animals received additional 
hormonal and/or chemotherapy. Groups 3 and 4 
received 0.58 mg/kg methotrexate intraperi- 
toneally for 5 consecutive days followed by a 16- 
day rest period, this regimen being continued 
until death. Animals in Group 4 received, in 
addition, 2 mg testosterone propionate in sesame 
oil subcutaneously 1 h prior to each dose of 
methotrexate. Group 5 received testosterone but 
no methotrexate. Sham operation or castration 
was performed on day 1 and chemotherapy and/or 
hormonal therapy in Groups 3-5 was instituted 
on day 8 of the experiment. All animals were 
weighed weekly and had tumours measured twice 
weekly in three axes by the same observer using 
a caliper. All animals were followed until death 
(Fig. I). 
Fifteen animals examined shortly after death 
had turnout measured in the standard fashion 
and in addition had an actual measurement of 
tumour volume by excision of the tumour and 
volume displacement. 
Analysis of turnout growth involved calcula- 
tion of relative tumour size over time and com- 
parison of the resul"tant areas under the curve 
(4). Relative turnout size is the ratio of actual 
tumour size to that on the day treatment was com- 
menced. 
RESULTS 
Analysis of turnout growth was restricted to  the 
first 29 days because of a rapid decline in animal 
survival beyond this point (Fig. 2). The median 
survival times for Groups 1-5 respectively were 
36, 37, 39, 33 and 35 days (Fig. 3). Ten animals 
were excluded from analysis because of death 
prior to day 29. Of these i0 animals 3 were in 
Group i, 3 in Group 3 and 4 in Group 4. No dif- 
ferences in the patterns of turnout growth were 
seen in these rats when compared to surviving 
animals in the respective groups, and the cause 
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The mean areas under the growth curves for 
Groups 1-5 respectively, were 7126.43, 4180.05, 
4008.93, 2158.86 and 5380.18. The group re- 
ceiving castration, testosterone and methotrexate 
(Group 4) exhibited the least turnout growth and 
was the only group significantly different from 
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Fig. 4. Median relative body weight for all treat- 
ment groups. Test. = testosterone, MTX = metho- 
trexate, Castr. = castration 
ferroni method of multiple comparisons using the 
Mann-Whitney test, p < 0.05). 
Analysis of animal weights was carried out 
using the same technique as previously described 
for turnout growth (Fig. 4) and revealed no sig- 
nificant differences among relative weight curves 
using the "area under the curve" method. 
For the 15 rats used to assess the correlation 
of in situ measurement of tumour size at time 
of death with actual volume, the Spearman rank 
correlation coefficient was r = 0.85, which indi- 
cated a strong positive correlation between the 
2 methods (p <0.01). 
D I S C U S S I O N  
Analysis of turnout growth curves in the R-3327-G 
model revealed that the group receiving castra- 
tion, testosterone and methotrexate (Group 4) had 
the least turnout growth and was the only group 
significantly different from control. The use of 
testosterone apparently increased the therapeutic 
effectiveness of the subsequent cell cycle specific 
chemotherapy. Several explanations can be of- 
fered for these results: 
i. Testosterone decreased turnout growth 
independently and added to the effectiveness of 
the subsequent chemotherapy. This possibility 
is eliminated by the fact that the addition of 
testosterone to castration increased, if anything, 
turnout growth more than castration alone. 
2. Testosterone acted synergistically with 
methotrexate to decrease tumour growth. Testos- 
terone is essential for the growth and maintenance 
of the mammalian prostate and results in in- 
creased DNA synthesis in the prostate of cas- 
trated rats. The androgen responsive Dunning 
R-3327-G prostatic adenocarcinoma presumably 
behaves similarly. The stimulation of DNA syn- 
thesis and mobilisatiion of cells into an actively 
dividing pool may have increased the effectiveness 
of methotrexate which is primarily toxic to cells 
in the S phase of the cell cycle (5). Alternatively, 
testosterone may have increased the cellular up- 
take of methotrexate by the turnout in a fashion 
unrelated to events in the cell cycle or a combina- 
tion of these events may have occurred. 
Animal survival is an event related to turnout 
growth and chemotherapy but is not entirely 
dependent on these factors. The failure to docu- 
ment increased survival in Group 4 does not ap- 
pear to be related to turnout growth because of 
the salutary effect of the treatment programme 
in this group. Testosterone and methotrexate 
in this regimen are not toxic to intact, non- 
turnout bearing animals (unpublished data) 
but the effect on turnout bearing animals 
is unknown. Further modifications of the treat- 
ment programme and/or the addition of supportive 
care (careful monitoring of fluid and electrolyte 
balance, etc. ) may allow the more definitive 
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separation of these 2 events, i.e. survival and 
tumour growth, while maintaining the apparent 
advantage in tumour control. 
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